$ELOX
Eloxx Pharmaceuticals, Inc.

2019 Q2 Form 10-Q Financial Statement

#000156459019029697 Filed on August 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.970M $9.560M
YoY Change -27.09% 2231.71%
% of Gross Profit
Research & Development $7.340M $4.150M
YoY Change 76.87% 59.92%
% of Gross Profit
Depreciation & Amortization $17.00K $25.00K
YoY Change -32.0% 257.14%
% of Gross Profit
Operating Expenses $7.340M $13.54M
YoY Change -45.8% 326.01%
Operating Profit -$13.54M
YoY Change 326.01%
Interest Expense -$140.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$138.0K $137.0K
YoY Change -200.73% -119.6%
Pretax Income -$14.45M -$13.41M
YoY Change 7.76% 567.16%
Income Tax
% Of Pretax Income
Net Earnings -$14.45M -$13.41M
YoY Change 7.78% 245.69%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$398.3K -$421.2K
COMMON SHARES
Basic Shares Outstanding 33.43M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $76.30M $63.41M
YoY Change 20.33% 211266.67%
Cash & Equivalents $49.33M $63.41M
Short-Term Investments $26.97M
Other Short-Term Assets $1.440M $560.0K
YoY Change 157.14% 124.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $77.74M $63.97M
YoY Change 21.52% 22746.43%
LONG-TERM ASSETS
Property, Plant & Equipment $214.0K $302.0K
YoY Change -29.14% 504.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K
YoY Change
Total Long-Term Assets $1.303M $302.0K
YoY Change 331.46% -94.57%
TOTAL ASSETS
Total Short-Term Assets $77.74M $63.97M
Total Long-Term Assets $1.303M $302.0K
Total Assets $79.04M $64.27M
YoY Change 22.98% 999.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.473M $2.098M
YoY Change 17.87% 995.01%
Accrued Expenses $5.773M $2.258M
YoY Change 155.67% 583.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $2.231M
YoY Change
Total Short-Term Liabilities $10.99M $4.356M
YoY Change 152.36% 57.26%
LONG-TERM LIABILITIES
Long-Term Debt $12.31M $0.00
YoY Change
Other Long-Term Liabilities $520.0K
YoY Change
Total Long-Term Liabilities $12.31M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.99M $4.356M
Total Long-Term Liabilities $12.31M $0.00
Total Liabilities $23.30M $4.360M
YoY Change 434.38% -12.34%
SHAREHOLDERS EQUITY
Retained Earnings -$112.5M -$60.96M
YoY Change 84.57% -49.96%
Common Stock $169.3M $121.0M
YoY Change 39.93% 41319.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $55.22M $59.92M
YoY Change
Total Liabilities & Shareholders Equity $79.04M $64.27M
YoY Change 22.98% 999.57%

Cashflow Statement

Concept 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income -$14.45M -$13.41M
YoY Change 7.78% 245.69%
Depreciation, Depletion And Amortization $17.00K $25.00K
YoY Change -32.0% 257.14%
Cash From Operating Activities -$9.620M -$8.510M
YoY Change 13.04% 1568.63%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$40.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$26.85M
YoY Change
Cash From Investing Activities -$26.85M -$40.00K
YoY Change 67025.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 41.22M 53.67M
YoY Change -23.2% 17790.0%
NET CHANGE
Cash From Operating Activities -9.620M -8.510M
Cash From Investing Activities -26.85M -40.00K
Cash From Financing Activities 41.22M 53.67M
Net Change In Cash 4.750M 45.12M
YoY Change -89.47% -21585.71%
FREE CASH FLOW
Cash From Operating Activities -$9.620M -$8.510M
Capital Expenditures $0.00 -$40.00K
Free Cash Flow -$9.620M -$8.470M
YoY Change 13.58% 1560.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49326000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48606000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
473000
CY2019Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
43000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10993000
CY2019Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12306000
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
516000
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
402000
CY2019Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1539000
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
168848000
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
24000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112511000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
55224000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79039000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
dei Entity Shell Company
EntityShellCompany
false
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
26973000
CY2019Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
45000
CY2018Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
45000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1392000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1690000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
77736000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
50341000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
214000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
248000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
989000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
100000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
129000
CY2019Q2 us-gaap Assets
Assets
79039000
CY2018Q4 us-gaap Assets
Assets
50718000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2473000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
747000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
452000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
204000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48651000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24151000
elox Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
231000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5773000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6938000
CY2019Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
2231000
CY2018Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
122000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7807000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
360000
CY2018Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1129000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
129825000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-86145000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
42911000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50718000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40043365
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39914668
CY2019Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
128697
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7340000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6971000
CY2018Q2 elox Business Combination Acquisition Related Costs And Adjustment To Estimate On Accrued Expense
BusinessCombinationAcquisitionRelatedCostsAndAdjustmentToEstimateOnAccruedExpense
-167000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
234000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
109000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-339000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1726000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
568000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-281000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
63512000
elox Noncash Acquisition Of Treasury Shares
NoncashAcquisitionOfTreasuryShares
83000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
365000
elox Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-231000
us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
-79000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18812000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14208000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
33590000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
6750000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
101000
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
9000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26865000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-101000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
15000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
276000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1120000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
116000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
97000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46397000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53668000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
720000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
39361000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
49371000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63412000
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
45000
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000
CY2019Q2 elox Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations In Reconciliation
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsInReconciliation
49371000
CY2018Q2 elox Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations In Reconciliation
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsInReconciliation
63512000
us-gaap Interest Paid Net
InterestPaidNet
400000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
79000
elox Noncash Acquisition Of Treasury Shares
NoncashAcquisitionOfTreasuryShares
95000
elox Non Cash Issuance Of Shares Upon Exercise Of Warrants
NonCashIssuanceOfSharesUponExerciseOfWarrants
178000
elox Fair Value Of Warrants Issued In Connection With Long Term Debt
FairValueOfWarrantsIssuedInConnectionWithLongTermDebt
421000
elox Non Cash Final Payment On Debt Financing Obligation
NonCashFinalPaymentOnDebtFinancingObligation
900000
elox Non Cash Deferred Public Offering Costs In Accounts Payable And Accruals
NonCashDeferredPublicOfferingCostsInAccountsPayableAndAccruals
172000
elox Number Of Rare And Ultra Rare Disease Due To Premature Stoppage Of Codons
NumberOfRareAndUltraRareDiseaseDueToPrematureStoppageOfCodons
1800
CY2019Q2 elox Cash And Cash Equivalent And Available For Sale Debt Securities
CashAndCashEquivalentAndAvailableForSaleDebtSecurities
76299000
CY2019Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2019Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
49326000
CY2019Q2 elox Cash And Cash Equivalent And Available For Sale Debt Securities Amortized Cost
CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAmortizedCost
76275000
CY2019Q2 elox Cash And Cash Equivalent And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
24000
CY2019Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2019Q2 us-gaap Prepaid Insurance
PrepaidInsurance
272000
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
251000
CY2019Q2 elox Contract Receivable Current
ContractReceivableCurrent
27000
CY2018Q4 elox Contract Receivable Current
ContractReceivableCurrent
20000
CY2018Q4 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
864000
CY2018Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
555000
CY2019Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
468000
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
254000
CY2019Q2 us-gaap Depreciation
Depreciation
17000
CY2018Q2 us-gaap Depreciation
Depreciation
25000
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1903000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2562000
CY2019Q2 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2315000
CY2018Q4 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3086000
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1191000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
985000
CY2019Q2 elox Accrued Interest On Debt
AccruedInterestOnDebt
100000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
264000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
305000
CY2018 elox Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P3Y11M1D
elox Class Of Warrant Or Right Granted Expiration Period
ClassOfWarrantOrRightGrantedExpirationPeriod
P10Y
elox Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P4Y3M
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
421000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2658000
CY2019Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-11917000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
34433000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
90000
CY2019Q2 elox Restricted Stock Vested During Period Value
RestrictedStockVestedDuringPeriodValue
-111000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3016000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
21361000
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
200000
elox Operating Lease Estimated Incremental Borrowings Rate
OperatingLeaseEstimatedIncrementalBorrowingsRate
0.08
CY2019Q2 elox Operating Lease Present Value At Inception
OperatingLeasePresentValueAtInception
1500000
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y18D
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
276000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
493000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
310000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1079000
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
90000
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
989000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
541000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
490000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
310000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1341000
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4583000
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5000000
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
5000000
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
417000
CY2019Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
15000000
CY2019Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1363000
CY2019Q2 us-gaap Long Term Debt
LongTermDebt
13637000
CY2019Q2 elox Long Term Debt Maturities Final Fee Due
LongTermDebtMaturitiesFinalFeeDue
900000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
CY2019Q1 elox Restricted Stock Vested During Period Value
RestrictedStockVestedDuringPeriodValue
-121000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
735000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-8591000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
13505000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
97000
CY2018Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
31000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6178000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
59916000
CY2019Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
40834
elox Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
40834
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
400000
CY2019Q2 elox Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
59707
CY2019Q2 elox Class Of Warrant Or Right Exercised In Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedInPeriodWeightedAverageExercisePrice
3.01
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
347241
elox Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
59707
elox Class Of Warrant Or Right Forfeited
ClassOfWarrantOrRightForfeited
4474
CY2019Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
323894
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.77
elox Class Of Warrant Or Right Granted In Period Weighted Average Exercise Price
ClassOfWarrantOrRightGrantedInPeriodWeightedAverageExercisePrice
11.02
elox Class Of Warrant Or Right Exercised In Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedInPeriodWeightedAverageExercisePrice
3.01
elox Class Of Warrant Or Right Forfeited In Period Weighted Average Exercise Price
ClassOfWarrantOrRightForfeitedInPeriodWeightedAverageExercisePrice
40.00
CY2019Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.32
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3261719
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1123900
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6913000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
61790
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
85802
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4238027
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
922759
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.09
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.13
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.87
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.48
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.70
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.51
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M21D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y21D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y5M1D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11650373
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4038764
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1695189
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3016000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6178000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5674000
CY2019Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
206000
CY2018Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
145000
us-gaap Interest And Other Income
InterestAndOtherIncome
494000
us-gaap Interest And Other Income
InterestAndOtherIncome
145000
CY2019Q2 us-gaap Investment Income Net
InvestmentIncomeNet
129000
us-gaap Investment Income Net
InvestmentIncomeNet
131000
CY2019Q2 us-gaap Interest Expense Other
InterestExpenseOther
473000
CY2018Q2 us-gaap Interest Expense Other
InterestExpenseOther
8000
us-gaap Interest Expense Other
InterestExpenseOther
703000
us-gaap Interest Expense Other
InterestExpenseOther
51000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5114433
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5088542

Files In Submission

Name View Source Status
0001564590-19-029697-index-headers.html Edgar Link pending
0001564590-19-029697-index.html Edgar Link pending
0001564590-19-029697.txt Edgar Link pending
0001564590-19-029697-xbrl.zip Edgar Link pending
elox-10q_20190630.htm Edgar Link pending
elox-20190630.xml Edgar Link completed
elox-20190630.xsd Edgar Link pending
elox-20190630_cal.xml Edgar Link unprocessable
elox-20190630_def.xml Edgar Link unprocessable
elox-20190630_lab.xml Edgar Link unprocessable
elox-20190630_pre.xml Edgar Link unprocessable
elox-ex311_8.htm Edgar Link pending
elox-ex312_9.htm Edgar Link pending
elox-ex321_6.htm Edgar Link pending
elox-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending